hlx70
mAbexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 9, 2020 (NCT05429385)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04561076 | Phase 1 | Dec 9, 2020 | Government of China, Hengenix Biotech Inc, Parexel, Sanyou Biopharmaceuticals |
| NCT05429385 | Phase 1 | Dec 9, 2020 | Government of China, Hengenix Biotech Inc, Sanyou Biopharmaceuticals, Shanghai Henlius Biotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 0 | 1 | 2020 |
| Hengenix Biotech Inc | For profit | 2 | 1 | 1 | 2020 |
| Sanyou Biopharmaceuticals | For profit | 2 | 0 | 1 | 2020 |
| Parexel | For profit | 1 | 0 | 1 | 2020 |
| Shanghai Henlius Biotech | For profit | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1